CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...

Institute for OneWorld Health

Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clover Biopharmaceuticals

Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.

AlphaRx

AlphaRx, Inc. is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.